Table 3.

Mixed Model of Daily Morning Serum Glucose (MSG), during Day 1–10 after Allogeneic HSCT.

Estimated MSG Absent Risk Factors Below	5.27 (4.88–5.68) mmol/L
	Percent Change (95% CI) in MSG per Risk Factor	p
Hispanic Recipient with Unrelated Donor	+17.15 (8.42–26.58)	<0.0001
Sex of Recipient, GVHD Prophylaxis
Male, Tacrolimus-based Prophylaxis	+11.91 (4.91–19.37)	<0.001
Male, Other Prophylaxis	+13.08 (4.10–22.83)	0.004
Female, Tacrolimus-Based Prophylaxis	+7.80 (1.02– 15.03)	0.024
Female, Other Prophylaxis	0
Day 1 Post-Transplantation	+9.82 (6.72–13.01)	<0.0001
TBI-based Myeloablative Conditioning	+8.60 (4.55–12.81)	<0.0001
TPN, Current Day	+8.68 (4.43–13.09)	<0.0001
TPN, For Each Preceding Day of Use	+1.20 (0.76–1.65)	<0.0001
Per One Step Increase in Category of BMI *	+6.62 (4.53–8.76)	<0.0001

^*Categories of Body Mass Index: Lean (18–<21), Normal (21–<25), Overweight (25–<30), Obese (30–48)